医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Medtech Startup CoreTissue BioEngineering to Be the First Japanese Startup at JPOD @ Boston

2022年03月16日 PM12:19
このエントリーをはてなブックマークに追加


 

YOKOHAMA, Japan

CoreTissue BioEngineering Inc., a medical device company developing an artificial ligament derived from decellularized animal tissue, was accepted into Johnson & Johnson Innovation – JPOD @ Boston.

CoreTissue BioEngineering will expand its footprint and accelerate business development in the US through its support team and select key opinion leaders (KOLs).

About CoreTissue BioEngineering Inc.

Based in Yokohama, Japan, CoreTissue BioEngineering, Inc. is a spinout company from Waseda University in Japan. We feel our team of Harvard-trained biomedical scientist, seasoned senior management in medical device development, and experienced clinical research professional has the right talents to carry this mission to potential success.

Following our success in developing artificial ligament for ACL reconstruction surgery, we plan to further apply our technology platform to the development of medical devices for the broader human musculoskeletal system.

CoreTissue BioEngineering has already validated a proof-of-concept of the product in an ovine large animal study with a prototype developed using these technologies. The company has received strong backing from the Japanese government, the Japan Agency for Medical Research and Development (AMED) for development from early feasibility through pivotal trial.

For more information, visit https://www.coretissue.com/?lang=en

View source version on businesswire.com: https://www.businesswire.com/news/home/20220302006183/en/

CONTACT

Chiaki Waki

CoreTissue BioEngineering Inc.

Email: chiaki.waki@coretissue.com

Tel: +81-80-7638-1286

Related Posts Plugin for WordPress, Blogger...
TimeLine:

同じカテゴリーの記事 

  • Genuv Announces Preclinical Data to be Released at Two Medical Conferences in June
  • IntelliCentrics Seeks Strategic Alliance With Taiwanese Health Insurance Providers to Serve Millions of Taiwanese Patients Ensuring They Have Remote Access to Trusted, High Quality Healthcare.
  • 中智全球寻求与台湾医疗保险公司结成战略联盟,为数百万台湾患者提供服务,确保他们能够远程获得可靠及优质的医疗保健服务。
  • Sermo调查显示,今年ASCO的与会肿瘤学家对新的肺癌和乳腺癌研究最感兴趣
  • 訂正・差し替え SCAI 2022 Scientific Meeting で心原性ショックの予後改善に向けた Impella の研究と進歩を大きく紹介